BA: Raising Target Price Post 1Q and Reiterate Overweight Rating
Key Points We’re updating our forecast for BA post the firm’s 1Q earnings release earlier this week as we raise our target price and reiterate our Overweight rating on the ......
Alembic Global Advisors is an independent equity research firm offering differentiated, experienced financial analysis on a variety of global industrial sectors. Our goal is to provide high quality, proprietary and actionable research into company, industry and broader macro trends on a truly global level.
Since its founding in 2009, Alembic has expanded from its core global chemical coverage to the aerospace & defense sector. Our analysts have been recognized by industry publications Institutional Investor, FT/Starmine and Extel.2 research analysts covering 35 companies across 3 industries (Chemicals and Aerospace & Defense). Our coverage list continues to grow as we remain focused on delivering our best-in-class research product.
Through our corporate access events we provide unique opportunities to meet with a select group of industry leaders, offering the chance to gain unique insights from people operating at the highest levels of their respective industries.
In addition to highly analytical deep dive research surrounding our specific equity coverage, we provide our macro view of each industry against the global backdrop of current events and how we see them shaping the future. We leverage our various areas of expertise to produce a collaborative cross-sector research product. This non-siloed approach allows us to maximize our areas of expertise, ultimately achieving a more dynamic and in-depth level of insight.
Not a client? Please contact Stephen Matthews – stephen.matthews@alembicglobal.com – to learn more about our research subscription offerings.
Access is limited to Alembic Global Advisors clients.
Key Points We’re updating our forecast for BA post the firm’s 1Q earnings release earlier this week as we raise our target price and reiterate our Overweight rating on the ......
Key Points Q1’25 EBITDA and EPS miss Near-term outlook commentary was mixed We rate LYB shares Neutral with a revised down 12-month target price of USD67 per share Summary LyondellBasell ......
Key Points We’re lowering our forecast and target price for HXL post the firm’s 1Q earnings report earlier this week, though we’re maintaining our Overweight rating. Our target price declines ......
Key Points Q1’25 EPS and EBITDA beat but Q2’25 guidance below consensus Alberta project delayed and further cost cuts announced. European review expanded We rate Dow Inc. shares Neutral, with ......
Key Points We’re updating our forecast for RTX post yesterday’s 1Q25 earnings report and we’re lowering our target price by USD17 to USD132. RTX reported a solid 1Q in several ......
Key Points Chemical equities’ performance is far worse than what we’ve seen in recessionary periods over the last 60 years, suggesting limited downside and significant upside Sector balance sheets and ......